Accuray reports Q1 EPS (18c) vs (4c) last year

Reports Q1 revenue $93.9M vs $101.5M last year. “As the new CEO of Accuray (ARAY), I have a tremendous amount of respect for what our radiotherapy systems can do to improve cancer patients’ lives for the better. While our first quarter results were soft, we were pleased to see continued expansion of our CyberKnife(R) and Radixact(R) Systems into new hospitals and markets, and we are excited about the introduction of Accuray Stellar and its potential in the U.S., where it is currently available for sale,” said Steve La Neve.